Editorial

641 Pioglitazone, Nuclear Receptors, and Aerodigestive Prevention
Frank G. Ondrey

Minireview

645 Scented Candles as an Unrecognized Factor that Increases the Risk of Bladder Cancer; Is There Enough Evidence to Raise a Red Flag?
Jan Adamowicz, Kajetan Juszczak, Slawomir Poletajew, Shane Vontelin Van Breda, Marta Pokrywczyńska, and Tomasz Drewa

Research Articles

653 Bufalin, a Traditional Chinese Medicine Compound, Prevents Tumor Formation in Two Murine Models of Colorectal Cancer
Xiao Sun, Tony T.H. Ng, Kathy W.Y. Sham, Lin Zhang, Matthew T.V. Chan, William K.K. Wu, and Christopher H.K. Cheng

667 Smoking, Helicobacter Pylori Serology, and Gastric Cancer Risk in Prospective Studies from China, Japan, and Korea
Julia Butt, Matthew G. Varga, Tianyi Wang, Shoichiro Tsugane, Taichi Shimazu, Wei Zheng, Christian C. Abnet, Keun-Young Yoo, Sue K. Park, Jeongseon Kim, Sun Ha Je, You-lin Qiao, Xiao-Ou Shu, Tim Waterboer, Michael Pawlita, and Meira Epplein

675 Sedentary Behavior and Prostate Cancer: A Systematic Review and Meta-Analysis of Prospective Cohort Studies
Felix F. Berger, Michael F. Leitzmann, Andrea Hillereiner, Anja M. Sellmeier, Maria Eleni Prokopidi-Danisch, Maximilian Burger, and Carmen Jochem

689 Evaluating the Utility and Prevalence of HPV Biomarkers in Oral Rines and Serology for HPV-related Oropharyngeal Cancer

701 Implementation of HPV-based Cervical Cancer Screening Combined with Self-sampling Using a Midwifery Network Across Rural Greece: The GRECOSELF Study

711 Effect of Bazedoxifene and Conjugated Estrogen (Duavee) on Breast Cancer Risk Biomarkers in High-Risk Women: A Pilot Study

721 A Randomized Phase II Trial of Pioglitazone for Lung Cancer Chemoprevention in High-Risk Current and Former Smokers
Robert L. Keith, Patrick J. Blatchford, Daniel T. Merrick, Paul A. Bunn Jr, Brandy Bagwell, Lori D. Dwyer-Nield, Mary K. Jackson, Mark W. Geraci, and York E. Miller
Table of Contents

CORRECTION

731 Correction: Cancer-Specific Production of N-Acetylaspartate via NAT8L Overexpression in Non-Small Cell Lung Cancer and Its Potential as a Circulating Biomarker

EXPRESSION OF CONCERN

733 Expression of Concern: Tobacco-Specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder Cancer

ABOUT THE COVER

No effective chemopreventive agents for lung cancer exist. Prostacyclin overexpression or administration of the stable prostacyclin analog, iloprost, is highly effective in preventing adenoma formation in multiple murine models of chemical carcinogenesis, including a tobacco smoke–induced tumor model. Oral iloprost is effective in improving premalignant dysplasia in former smokers in a Phase II trial, but the drug is not currently available. Basic studies have supported a PPARγ-mediated mechanism for iloprost’s chemopreventive activity. Pioglitazone is a thiazolidinedione PPARγ activator and has been shown to be chemopreventive in multiple preclinical models. Keith and colleagues carried out a placebo-controlled Phase II trial (beginning on page 721) of oral pioglitazone in high-risk current or former smokers with sputum cytologic atypia or known endobronchial dysplasia. Although pioglitazone did not show efficacy in improving premalignant dysplasia in either current or former smokers, specific lesions showed histologic improvement. The results suggest that chemopreventive activity of iloprost is not purely mediated through PPARγ. Further study will be needed to better characterize responsive dysplasia. The cover image depicts the structure of pioglitazone, the drug tested in this study.